- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03142204
[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy
Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG (VisAcT), a Positron Emission Tomography Tracer for Imaging the Activation of the Immune System in Cancer Patients Who Have Received or Are Expected to Receive Immunotherapy and/or Radiation Therapy
Study Overview
Detailed Description
This is an exploratory Phase 1, prospective study assessing the biodistribution and radiation dosimetry of the Positron Emission Tomography [18F]FAraG (VisAcT) in cancer patients selected for immunotherapy and/or radiation therapy. Each patient may have up to two [ 18F]FAraG PET imaging sessions, a baseline scan and a post start of immunotherapy scan. For each imaging session, patients will receive a single injection of [18F]FAraG and undergo a whole-body PET scans an hour after injection of the tracer. Following each imaging session, the patient will be called within 72 hours to note any side effects.
Optional - Blood samples may be collected at up to 9 time points post-injection to analyze whole-blood/plasma time activity of [18F]FAraG in addition an urine sample may be collected post scan.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Robert R Flavell, M.D., Ph.D.
- Phone Number: 917-509-8679
- Email: robert.flavell@ucsf.edu
Study Contact Backup
- Name: Henry VanBrocklin, Ph.D.
- Phone Number: 415-353-4569
- Email: henry.vanbrocklin@radiology.ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94107
- Recruiting
- UCSF Imaging Center at China Basin
-
Contact:
- Maya Aslam
- Phone Number: 415-514-8987
- Email: Maya.Aslam@ucsf.edu
-
Contact:
- Katherine Wu
- Phone Number: 415-353-9437
- Email: katherine.wu@ucsf.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cancer patients with identified tumor mass
- Cancer patients expected to undergo immunotherapy and/or radiation therapy
Exclusion Criteria:
- Under the age of 18
- Pregnant women
- Women who are breastfeeding
- Individuals with known or suspected substance abuse
- Individuals unable or unwilling to comply with the study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visualize biodistribution of the PET tracer [18F]F-AraG pre-immunotherapy
Time Frame: Up to 6 weeks before immunotherapy is administered
|
Whole-body [18F]F-AraG PET scan will be performed after intravenous injection of the PET tracer.consecutive
time points the day of the intravenous injection of the PET tracer.
|
Up to 6 weeks before immunotherapy is administered
|
|
Visualize biodistribution of the PET tracer [18F]F-AraG post start of immunotherapy
Time Frame: Up to 12 weeks after start of immunotherapy
|
Whole-body [18F]F-AraG PET scan will be performed after intravenous injection of the PET tracer.
|
Up to 12 weeks after start of immunotherapy
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert R Flavell, M.D., Ph.D., UCSF Department of Radiology & Biomedical Imaging
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 14-14488
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.